This page shows the latest Mimpara news and features for those working in and with pharma, biotech and healthcare.
be treated with Amgen's older drug Sensipar/Mimpara (cinacalcet) - and provided Amgen supplies the drug at an agreed discount.
Parsabiv (etelcalcetide) - a follow-up to Amgen's blockbuster Sensipar/Mimpara (cinacalcet) - has been given a green light to treat adult CKD patients on dialysis who develop secondary hyperparathyroidism (sHPT).
Sensipar/Mimpara blockbuster.
up to blockbuster Sensipar/Mimpara.
of Amgen's hyperparathyroidism and parathyroid carcinoma drug Mimpara.
AMG 416 meets objectives in hyperparathyroidism. One of the unsung heroes in Amgen's product portfolio is Sensipar/Mimpara for secondary hyperparathyroidism (HPT), which has grown fairly steadily since its launch
More from news
Approximately 1 fully matching, plus 11 partially matching documents found.
Creative agency PAN and sister digital agency DJM Solutions have won a prestigious Global Award for their animation of Mimpara Man’ for Amgen. ... Creative agency PAN and sister digital agency DJM Solutions have won a prestigious Global Award for their
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...